We showed that hGIC derived from mesenchymal GBM triggered activation of mTOR signalling in iMGL and mTOR‐dependent regulation of STAT3 and inhibition of NF‐κB signalling, in line with our findings in mouse models. The gene discussed is STAT3; the disease is glioblastoma.